

AMENDMENTS TO THE CLAIMS:

The following listing of the claims replaces all versions of previous claims in the application.

1.-4. (Cancelled)

5. (Currently Amended) A ~~cardioprotective~~-pharmaceutical preparation for ~~intravenous administration to~~ treating atrial arrhythmia in a mammal, said preparation comprising a ~~synergistic~~-combination of:

2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and ibutilide in a weight ratio of 10,000:1 to 1:1; or

2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and dofetilide in a weight ratio of 10,000:1 to 1:1;

or the physiologically tolerable salts thereof,

and a pharmaceutically innocuous solvent;

~~wherein said pharmaceutical preparation is formulated to deliver a dose of said 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide to said mammal at a rate of from about 0.3 mg/kg/h to about 3 mg/kg/h.~~

6.-12. (Cancelled)

13. (New) The cardioprotective pharmaceutical composition of claim 5, wherein said weight ratio is 100:1 to 5:1.